StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.41−0.17 (-10.76%)

Close on Nov 16, 2026Market cap $117.61MP/E –Yield –

Pyxis Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Pyxis Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $75.56M, up 14.6% year over year. For fiscal 2025 it was $73.70M, up 25.4% from the year before. The highest annual figure on record is $86.13M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$73.70M+25.4%
FY2024Dec 31, 2024$58.75M+18.5%
FY2023Dec 31, 2023$49.59M-42.4%
FY2022Dec 31, 2022$86.13M+68.7%
FY2021Dec 31, 2021$51.05M+464.3%
FY2020Dec 31, 2020$9.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.06M-6.3%
Q1 FY2026Mar 31, 2026$19.98M+17.2%
Q4 FY2025Dec 31, 2025$21.71M+54.8%
Q3 FY2025Sep 30, 2025$17.81M+0.4%
Q2 FY2025Jun 30, 2025$17.13M+22.8%
Q1 FY2025Mar 31, 2025$17.04M+30.8%
Q4 FY2024Dec 31, 2024$14.02M+20.8%
Q3 FY2024Sep 30, 2024$17.74M+20.8%
Q2 FY2024Jun 30, 2024$13.95M+22.5%
Q1 FY2024Mar 31, 2024$13.03M+9.5%
Q4 FY2023Dec 31, 2023$11.61M-61.1%
Q3 FY2023Sep 30, 2023$14.69M-22.8%
Q2 FY2023Jun 30, 2023$11.39M-33.7%
Q1 FY2023Mar 31, 2023$11.90M-40.7%
Q4 FY2022Dec 31, 2022$29.85M+313.1%
Q3 FY2022Sep 30, 2022$19.03M+142.5%
Q2 FY2022Jun 30, 2022$17.17M+435.7%
Q1 FY2022Mar 31, 2022$20.07M-38.8%
Q4 FY2021Dec 31, 2021$7.23M+130.2%
Q3 FY2021Sep 30, 2021$7.85M+223.7%
Q2 FY2021Jun 30, 2021$3.21M–
Q1 FY2021Mar 31, 2021$32.77M–
Q4 FY2020Dec 31, 2020$3.14M–
Q3 FY2020Sep 30, 2020$2.43M–

More Pyxis Oncology figures

See a number that looks wrong?